RxDoctor Payments Data

Sandra Tuero, MD

Emergency Medicine · Thousand Oaks, CANPI 1174561898

Payments from drug & device makers

$1,105in general payments, 2019–2025

Across 41 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$558
  • Otsuka America Pharmaceutical, Inc.$91
  • Boehringer Ingelheim$88
  • Abbott$65
  • Novo Nordisk$63
  • GSK$61
  • plus $179 from 7 others

What the payments were for

  • Food & beverage$1,105100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,105 in reported general payments places this provider in the 90th percentile of 6,006 emergency medicine providers in California.

See all emergency medicine providers in California

Medicare billing

Part B allowed, 2024
$33,857
Medicare patients
110
Services billed
368

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol49$37,083
JardianceEmpagliflozin34$32,579
OzempicSemaglutide32$29,300
LinzessLinaclotide22$18,629
DapagliflozinDapagliflozin Propanediol14$7,173
VascepaIcosapent Ethyl17$6,602
MyrbetriqMirabegron14$6,313
Dexlansoprazole DrDexlansoprazole18$5,205
Icosapent Ethyl18$3,558
Ezetimibe80$1,991
Rosuvastatin Calcium152$1,645
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,548
Albuterol Sulfate HfaAlbuterol Sulfate47$1,176
Atorvastatin Calcium170$1,145
Metformin Hcl255$989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$558$37,08349 claims
Boehringer IngelheimJardiance$88$32,57934 claims
Novo NordiskOzempic$63$29,30032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,006 emergency medicine providers in California.

Other emergency medicine in Thousand Oaks

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →